Clinical trial
A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies
NCT02538510 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies
- Lead sponsor
- University of Washington
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- October 8, 2015
- Completion date
- September 15, 2023
- Enrollment
- 50 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
head and neck squamous cell carcinoma, recurrent nasal cavity and paranasal sinus squamous cell carcinoma, recurrent nasopharynx carcinoma, recurrent salivary gland carcinoma, squamous cell carcinoma metastatic in the neck with occult primary, stage iii major salivary gland carcinoma, stage iii nasal cavity and paranasal sinus squamous cell carcinoma, stage iii nasopharyngeal carcinoma, stage iv nasopharyngeal carcinoma, stage iva major salivary gland carcinoma, stage iva nasal cavity and paranasal sinus squamous cell carcinoma, stage ivb major salivary gland carcinoma, stage ivb nasal cavity and paranasal sinus squamous cell carcinoma, stage ivc major salivary gland carcinoma, stage ivc nasal cavity and paranasal sinus squamous cell carcinoma